| Name | Title | Contact Details |
|---|
Elementary is a company specializing in advanced machine vision inspection, utilizing AI and automation to enhance manufacturing processes. Founded in mid-2017 by experienced professionals from various sectors, the company aims to develop a new generation of manufacturing products that rely on computer vision and AI. Their platform automates traceability scans and integrates AI, machine vision, and automation into production lines. This approach focuses on improving quality, traceability, and root cause analyses, making manufacturing processes more efficient. Elementary emphasizes a human-in-the-loop strategy, enhancing collaboration between humans and machines to optimize working conditions and outcomes. Based in Los Angeles, California, Elementarys team includes roboticists, computer scientists, designers, and engineers. The company has attracted significant funding, including a $30 million Series B round led by Tiger Global, to support its innovative solutions in manufacturing. Their technology is utilized by notable clients across various industries, including Toyota in the automotive sector.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Accounting 501 (formerly Pery Consulting Group, founded by Rafe Pery) includes a team of 25 consultants with a broad range of experience in the non-profit sector from the day-to-day transactional accounting level up to the CFO level. Accounting 501 works exclusively in the non-profit sector and assists organizations that are experiencing rapid growth or operational challenges such as…a financial crisis, staffing transitions, accounting system clean-up, merger/reorganization, the need to establish and/or fine tune systems, policies, and procedures. At Accounting 501, we specialize in assisting organizations with complex private and public funding sources to maximize grants and contracts and to ensure compliance with grant requirements. We understand the importance of cost allocation as well as cost center reporting as key to meeting the goals of the organization.
In a time when humanity needs to rethink the future to sustain life on this planet, we consider responsible business a necessary game changer. That is why we are a company that offers 100% organic cotton products for customers who seek delicious, sustainable goods of premium quality. We want our products to last long enough to be passed on. We create them to be enjoyed and used. And we insist on developing a new, sustainable standard of designed goods. #design #functionality #longlasting #newstandard #BCorp #GOTS #organic #feelgood